- Home
- MUC vs COLL Comparison
MUC vs COLL Comparison
Compare MUC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUC
- COLL
- Stock Information
- Founded
- MUC 1997
- COLL 2002
- Country
- MUC United States
- COLL United States
- Employees
- MUC N/A
- COLL N/A
- Industry
- MUC Investment Bankers/Brokers/Service
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- MUC Finance
- COLL Health Care
- Exchange
- MUC Nasdaq
- COLL Nasdaq
- Market Cap
- MUC 1.0B
- COLL 910.2M
- IPO Year
- MUC N/A
- COLL 2015
- Fundamental
- Price
- MUC $10.73
- COLL $29.85
- Analyst Decision
- MUC
- COLL Strong Buy
- Analyst Count
- MUC 0
- COLL 5
- Target Price
- MUC N/A
- COLL $43.60
- AVG Volume (30 Days)
- MUC 292.8K
- COLL 456.4K
- Earning Date
- MUC 01-01-0001
- COLL 05-08-2025
- Dividend Yield
- MUC 4.19%
- COLL N/A
- EPS Growth
- MUC N/A
- COLL 43.56
- EPS
- MUC N/A
- COLL 1.86
- Revenue
- MUC N/A
- COLL $631,449,000.00
- Revenue This Year
- MUC N/A
- COLL $20.00
- Revenue Next Year
- MUC N/A
- COLL $3.93
- P/E Ratio
- MUC N/A
- COLL $16.00
- Revenue Growth
- MUC N/A
- COLL 11.41
- 52 Week Low
- MUC $9.19
- COLL $27.28
- 52 Week High
- MUC $11.30
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- MUC 42.75
- COLL 50.32
- Support Level
- MUC $10.61
- COLL $29.33
- Resistance Level
- MUC $10.81
- COLL $30.84
- Average True Range (ATR)
- MUC 0.08
- COLL 0.84
- MACD
- MUC -0.01
- COLL 0.07
- Stochastic Oscillator
- MUC 32.86
- COLL 56.29
About MUC Blackrock MuniHoldings California Quality Fund Inc.
BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment firm. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.